Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across biomedical AI, cancer, cardiovascular diseases, immunity, age-related, rare and infectious diseases.

          Learn more

        • Biomedical AI
        • Cancer Innovations
        • Cardiovascular Research
        • Infection & Immunity
        • Rare Diseases & Gene Therapy
        • Laboratories
        • Impact
        • Technologies
        • Commercialisation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research.

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your will
        • Donate in memory
        • Advise on our research
  • Careers & students
        • Careers & Students

          Postdoctoral and postgraduate students can work alongside world-leading medical researchers within state-of-the-art research facilities.

        • Careers
        • Study opportunities
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events.

        • News
        • Statements
        • Events
        • Real stories
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges.

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Animals in research
        • Contact
  • Donate
    Centenary Institute > News > Breakthrough in preventing the spread of melanoma

Breakthrough in preventing the spread of melanoma

Date time 19 December, 2018
News Type News type Media release

Researchers at the Centenary Institute in Sydney have led a study which has uncovered a brand-new target for melanoma metastasis; providing an improved understanding of how the cancer spreads and opening the door for more effective treatments.

Australia and New Zealand have the highest rates of melanoma in the world. More than 14,000 new cases of melanoma are estimated to have occurred in 2018.[1] Melanoma is the most common cancer in young Australians (aged 15-39), and it kills more young Australians than any other single cancer.

The primary cause of death in melanoma patients is metastasis – the process by which cancer spreads to other areas of the body. While there have been recent advances in targeted and immune-based treatments, advanced stage melanoma remains a clinical challenge with a particularly poor prognosis.

Scientists from the Centenary Institute, in collaboration with 11 other Australian research institutions, have identified a specific protein (called RAB27A) as a key driver of melanoma metastasis. This occurs via the secretion of pro-invasive exosomes; tiny bubble-like structures which are expelled from cells.

During the study, the researchers discovered that silencing the expression of RAB27A reduced a certain population of exosomes delivering pro-invasion messages, which led to reduced metastasis.

Lead author and PhD researcher in Centenary’s Immune Imaging Program, Dajiang Guo, says the discovery provides a new way through which researchers can better target and treat melanoma.

“From our findings, we propose RAB27A is a novel prognostic factor, which means it could provide clinicians with a new way to determine a melanoma patient’s future health outcome,” says Mr. Guo.

“We also believe it could provide a brand new therapeutic target for the prevention of metastasis, which would improve the efficacy of future treatments. This is significant because metastasis is the main cause of death in melanoma patients.”

 

View the full media release as a PDF.

Read the paper published in the International Journal of Cancer.

[1] The Australian Institute of Health and Welfare, Cancer Compedium: information and trends by cancer type.

Media enquires

For all media and interview enquiries, please contact Tony Crawshaw

Phone number Phone Number +61 402 770 403

Email Email t.crawshaw@centenary.org.au

Media Release

Download

Recent Stories

  • New grant targets longer-lasting islet cell treatments for type 1 diabetes

    Dr Lise Hunault, a researcher in the Centenary Institute’s Centre for Biomedical AI, has been awarded a major research grant from Breakthrough T1D, the leading global type 1 diabetes research and advocacy organisation, to advance islet-cell replacement therapies for type 1 diabetes.
    News Type: Research News
    Date 16 Mar 2026
  • Centenary marks International Women’s Day with inspiring speakers

    The Centenary Institute community came together to celebrate International Women’s Day 2026, with a special event highlighting this year’s Australian theme, ‘Balancing the Scales.’
    News Type: Community
    Date 11 Mar 2026
  • Vaxosome launched to develop next-generation mRNA vaccines

    A new biotechnology company, Vaxosome, has been launched to develop next-generation vaccines aimed at tackling some of the world’s most challenging infectious diseases.
    News Type: Research News
    Date 10 Mar 2026
  • Centenary partners in transformative national liver health program

    The Snow Medical Research Foundation has today announced major long-term funding of $15.5 million for a new national research program targeting fatty liver disease, a condition that affects up to one in three Australians. The Centenary Institute will play a key role in the collaborative effort.
    News Type: Research News
    Date 05 Mar 2026

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About us
  • Governance
  • Corporate information

Research

  • Our researchers
  • News

Careers & studies

  • Career opportunities
  • Student opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement
  • Staff Intranet

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Contact Privacy

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram